论文部分内容阅读
目的观察左旋卡尼汀联合重组人促红细胞生成素(rhu-EPO)治疗血透患者肾性贫血的临床疗效。28例维持血液透析的患者随机分为二组,A组14例,采用rhu-EPO 3000IUIU皮下注射2～3次/周治疗;B组14例,透析后静脉注射左旋卡尼汀1g,同时应用rhu-EPO 3000IU皮下注射2～3次/周治疗。观察二组病人血浆白蛋白、血红蛋白、红细胞体积的变化。结果治疗12周,B组血浆白蛋白、血红蛋白较A组明显上升,差异有显著性(P<0.05),而且rhu-EPO用量明显低于A组。结论左旋卡尼汀可改善维持血液透析患者的状态,提高rhu-EPO的疗效,减少rhu-EPO的用量。
Objective To observe the clinical efficacy of levocarnitine combined with recombinant human erythropoietin (rhu-EPO) in the treatment of renal anemia in hemodialysis patients. 28 cases of hemodialysis patients were randomly divided into two groups, A group of 14 cases, using rhu-EPO 3000IUIU subcutaneous injection of 2 to 3 times / week treatment; B group of 14 patients after intravenous injection of levocarnitine 1g, at the same time application rhu-EPO 3000IU subcutaneous injection of 2 to 3 times / week treatment. The changes of plasma albumin, hemoglobin and erythrocyte volume in the two groups were observed. Results After 12 weeks of treatment, plasma albumin and hemoglobin in group B were significantly higher than those in group A (P <0.05), and the amount of rhu-EPO in group B was significantly lower than that in group A. Conclusion L-carnitine can improve the maintenance of hemodialysis patients, improve the efficacy of rhu-EPO and reduce the dosage of rhu-EPO.